Scabies: an ancient global disease with a need for new therapies

Jackson Thomas1*, Greg M Peterson2, Shelley F Walton3, Christine F Carson4,5, Mark Naunton1 and Kayya E Baby6

Abstract
Background: Scabies is an ancient disease (documented as far back as 2500 years ago). It affects about 300 million people annually worldwide, and the prevalence is as high as about 60% in Indigenous and Torres Strait Islander children in Australia. This is more than six times the rate seen in the rest of the developed world. Scabies is frequently complicated by bacterial infection leading to the development of skin sores and other more serious consequences such as sepsicaemia and chronic heart and kidney diseases. This causes a substantial social and economic burden especially in resource poor communities around the world.

Discussion: Very few treatment options are currently available for the management of scabies infection. In this manuscript we briefly discuss the clinical consequences of scabies and the problems found (studies conducted in Australia) with the currently used topical and oral treatments. Current scabies treatment options are fairly ineffective in preventing treatment relapse, inflammatory skin reactions and associated bacterial skin infections. None have ovicidal, antibacterial, anti-inflammatory and/or anti-pruritic properties. Treatments which are currently available for scabies can be problematic with adverse effects and perhaps of greater concern the risk of treatment failure. The development of new chemical entities is doubtful in the near future. Though there may be potential for immunological control, the development of a vaccine or other immunotherapy modalities may be decades away.

Summary: The emergence of resistance among scabies mites to classical scabicides and ineffectiveness of current treatments (in reducing inflammatory skin reactions and secondary bacterial infections associated with scabies), raise serious concerns regarding current therapy. Treatment adherence difficulties, and safety and efficacy uncertainties in the young and elderly, all signal the need to identify new treatments for scabies.

Keywords: Scabies, Resistance, MDA, Ivermectin, Permethrin, Benzyl peroxide, Treatments, Indigenous, Aboriginal

Background
Scabies has existed for at least 2500 years [1] and currently affects 300 million people annually worldwide. Its listing as a neglected tropical disease by the World Health Organization (WHO) in 2013 [2] recognised the neglect in public and private sector expenditure on this problem, the lack of attention at local, national, and international levels, and the higher incidence of this infection amongst the poor. In Australia it affects about 6 in 10 Aboriginal and Torres Strait Islander children at any given time, more than six times the rate seen in the rest of the developed world [3, 4]. The sequela of scabies predisposes affected children to sepsis and other non-suppurative invasive infections (e.g. lymphadenopathy, acute post-streptococcal glomerulonephritis (APSGN) and rheumatic fever) [5]. Outbreaks of APSGN usually coincide with scabies outbreaks, which can contribute to the development of chronic kidney disease and subsequent renal failure in adulthood [6]. It is usually reported in Australian Aboriginal communities, other Oceanic nations (Papua New Guinea, Fiji, Solomon Islands, Vanuatu) [7], and in some parts of India, Chile and Trinidad [5], and is uncommon outside these communities. APSGN outbreaks do not always coincide with scabies outbreaks elsewhere in the developed world. Scabies infestation has a negative impact on the quality of life for infected individuals (similar to that of psoriasis) resulting in substantial stigmatisation and ostracism [8].

In this manuscript we focus on the challenges found with diagnosis and treatment, emerging resistance among scabies mites, and the need for further research in this
field to identify new and alternative therapies for the treatment and prophylaxis of scabies.

Discussion

Diagnosis

At present there is no accurate means of diagnosing scabies in various clinical settings. Presumptive diagnosis is often made on the basis of clinical signs, and a history of contact with other scabies cases [9]. In practice (especially in resource poor settings), identifying scabies mite from patient’s skin is challenging, and a negative result by even experienced clinical staff, does not rule out scabies. A positive response to therapy cannot exclude the spontaneous disappearance of a skin condition other than scabies, and a negative response to the first-line treatment option does not exclude scabies, especially with growing resistance among scabies mites [9]. Recent findings in this field, e.g. serodiagnosis [10] shows promising potential; however, more research is required to evaluate its efficiency in tropical clinical settings.

Treatments

There are several recommended treatment options for scabies and these have been discussed in detail in a 2010 Cochrane review [11]. There are few obvious safe and effective scabicides currently (Table 1 and 2), and treatment effectiveness can vary between clinical settings [12]. So far, there is no international consensus on the appropriate schedule for scabies treatment, and recommendations in one nation may not be appropriate in others [8]. The first line treatment options are topical agents and require whole body application for many hours duration [13]. Multiple treatment doses are often recommended over days to weeks. Topical or oral antibiotic therapy may be required if secondary skin infection has developed [14]. It has also been advised that close contacts of people with scabies should be treated simultaneously, as they may be infected without yet manifesting symptoms, and so can act as a reservoir of infection [14, 15]. Treating the contacts may prevent re-infection of the index cases following treatment [13]. The logistics to treat all contacts simultaneously are significant as it requires identification and treatment of all contacts of an index case (e.g. family members, other coinhabitants, medical and other supporting staff and others who may come in contact with the index cases) [14, 16].

Most treatments (Table 2) are potentially hazardous and are associated with moderate to severe side effects (e.g. secondary eczematisation, oedema, erosions and/or pyoderma) [17–22]. The most frequent complication of topical scabicides is persisting post-scabies eczema (generalised eczematous dermatitis) resulting from irritant effects of the various formulations [23]. These may escalate xerosis and worsen delayed-type eczema. Further, it may be difficult to treat patients with secondary eczematisation, erosions or ulcers using currently available topical scabicidal agents such as permethrin, lindane, benzoyl peroxide and sulphur, as they can cause serious cutaneous and systemic side-effects in addition to the problem of compliance, resulting in poor treatment uptake [24].

Oral ivermectin is not widely available and has not been approved for the management of scabies in many countries [8]. At present, there is some observational evidence of its effectiveness in controlling scabies outbreaks in institutional settings including nursing homes [5]. However; the safety or efficacy of ivermectin, the sole oral therapy available, has not been well-established in the elderly, patients with impaired liver function (potential for toxicity resulting from long elimination half-life [36 h]), children (aged <5 years) and pregnant women, where the blood–brain barrier is incompletely developed in the foetus, raising the potential for neurotoxicity [12]. Because of the drug’s lipophilicity, ivermectin may be poorly distributed in the astereotic stratum corneum of the elderly compared to younger patients, leading to mediocre therapeutic responses in the former patient cohort and requiring combination therapy with topical scabicides [12]. Ivermectin is not ovicidal, does not adequately penetrate the thick egg shell of the scabies mite, and is also ineffective against the younger stages of the parasite (whose nervous system is poorly developed), resulting in delayed therapeutic response [25].

Mass drug administration (MDA) programs have been attempted to use ivermectin to control scabies in endemic communities around the world [26]. However, such programs’ superiority over alternative topical treatment is questionable [27, 28]. Ivermectin is indicated in Australia only for crusted scabies or cases of typical scabies when prior topical treatment has failed or has been contraindicated [29]. It is generally recommended that for maximum absorption ivermectin must be given in empty stomach [30], which is a challenge in community-based programs. Ivermectin administration can be labour-intensive since the weight of all patients and the pregnancy status of all women of childbearing age must be determined. Paradoxically, its use is not recommended in those under 5 years of age when these are the most vulnerable group (particularly among Aboriginal and Torres Strait Islander children) [29, 30]. Institutional outbreaks of scabies in aged care centres, prisons, hospital wards and kindergartens are not uncommon in developed counties. In Australia it is neither given to contacts of index cases, nor to households in heavily infected large communities, as the prescribing information does not support ivermectin administration to contacts of index cases [31].

Permethrin resistance is widespread in other ectoparasites [32]. Evidence of increasing acaricide resistance
leading to treatment failures has been reported (Table 1) [33–37]. In vitro sensitivity data of scabies mites from the last 10 years (Australian data) indicate that median survival times to leading acaricides (ivermectin and permethrin) have increased 2–3 fold [33, 34]. Treatment failure of permethrin as a scabicide in Indigenous communities in Australia (following MDA) and elsewhere has been documented and it is the slowest-acting acaricide (in vitro) in the Northern Territory, Australia [33, 38]. Permethrin resistance to scabies mites has been confirmed in

| Study                        | Indicative cure rate | Drugs and treatment regimen | Comments                                                                 |
|------------------------------|----------------------|-----------------------------|--------------------------------------------------------------------------|
| **Topical**                  |                      |                             |                                                                          |
| Benzyl benzoate              |                      |                             |                                                                          |
| [45] Moberg et al., 1984     | (43 %; 6/14)         | benzyl benzoate (22.5 %)    | case report                                                              |
| [46] Yonkosky et al., 1990   | (12 %; 23/195)       | benzyl benzoate (50 %)      | case study                                                               |
| [47] Nnoruka et al., 2001    | (48 %; 14/29)        | benzyl benzoate (22.5 %)    | clinical exploratory study                                               |
| [38] Glaziou et al., 1993    | (48 %; 10/21)        | benzyl benzoate (10 %)      | RCT                                                                      |
| **Permethrin**               |                      |                             |                                                                          |
| [33] Mounsey et al., 2008    | (80 %; 24/30)        | permethrin 5 % cream        | un-controlled case study                                                  |
| [34] Mounsey et al., 2009    | (80 %; 24/30)        | permethrin 5 % cream        | and (in vitro study)                                                     |
| [39] Pasay et al., 2008      |                      |                             | (in vitro study)                                                         |
| [30] Currie BJ 1999          | (0 %; 0/1)           | sulphur 5 % in an ointment   | case report                                                              |
| Sulphur                      |                      |                             |                                                                          |
| [51] Coskey RJ, 1979         | (0 %; 0/1)           | sulphur 5 % in an ointment   | case report                                                              |
| **Oral**                     |                      |                             |                                                                          |
| Ivermectin                   |                      |                             |                                                                          |
| [52] Glaziou et al., 1993    | (70 %; 16/23)        | single dose, 100 µg/kg      | RCT, poor efficacy partly attributed to the lower dose used in the study   |
| [30] Currie et al., 1994     | (0 %; 0/1)           | two doses, 200 µg/kg        | case report, crusted scabies                                            |
| [33] Currie BJ 1999          | (0 %; 0/1)           | five dose regimen, 200 µg/kg| crusted scabies, monthly administration failed to prevent reinfection    |
| [36] Currie et al., 2004     | (0 %; 0/2)           | seven doses, 270 µg/kg      | reinfection following seven doses, unpublished observations              |
| [53] Brooks, et al., 2002    | (56 %; 24/43)        | single dose, 200 µg/kg      | results evaluated at 3 weeks post treatment                             |
| [33] Mounsey et al., 2008    | (0 %; 0/7)           |                             | In vitro study                                                           |
| [41] van den Hoek et al., 2008 | (0 %; 0/7)          |                             | case report                                                              |
| [34] Mounsey et al., 2009    | (0 %; 0/7)           |                             | In vitro study                                                           |
| [42] Ly et al., 2009         | (30 %;16/53) single dose, 150–200 µg/kg | first RCT to report resistance of ivermectin |
| [43] Rizvi et al., 2011      | (78 %; 38/50) single dose, 200 µg/kg | quasi clinical study       |
| [54] Fujimoto et al., 2014   | (0 %; 0/1)           | 6000 µg/week* 3 + 12000 µg/week *3 | case report |
| [49] Saqib et al., 2012      | (0 %; 0/1)           |                             | quasi clinical study, re-infestation after successful treatment (7 %; 4/60) |
| [50] Huffam et al., 1997     | (60 %; 12/20)        | one-three doses, 200 µg/kg combined with topical scabicide and keratolytic therapy | crusted scabies |

---

Thomas et al. BMC Infectious Diseases (2015) 15:250  Page 3 of 6
an animal model and its likely resistance mechanism has also been documented [37, 39]. Since the first documented case in Australia in 1994 [40], there have been reports of resistance of *Sarcoptes scabiei* to ivermectin in vitro and in vivo, including treatment failure in clinical trials [30, 34, 41–43]. MDAs programs that encounter poor compliance increase the risk of developing resistance and targeted treatment of index cases and contacts may be a better approach [44].

**Conclusions**

- Availability of a ‘fool-proof’ diagnostic tool will enable the selective treatment of affected individuals, decrease the potential for escalating mite resistance, and reduce the need for mass treatment and the associated costs.
- Long-term adherence difficulties, safety and efficacy uncertainties in the young and elderly, and growing concerns over the development of resistance to classical scabicides, all signal the need to identify new treatment options for scabies (with greater levels of treatment compliance in MDA programs) to reduce the burden of infection in endemic settings and the morbidity and mortality associated with it.

**Abbreviations**

MDA: Mass Drug Administration Programs; WHO: World Health Organisation.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

Conception, literature search, design, data analysis: JT, GMP, SFW, CFC, KEB; wrote the manuscript: JT; Edited the manuscript: GMP, SFW, CFC, MN; All authors read and approved the manuscript.

**Authors’ details**

1Senior Lecturer in Pharmaceutics, Faculty of Health University of Canberra, Canberra, Australia

2Professor in Pharmacy, Associate Dean of Research, University of Tasmania, Hobart, Tasmania, Australia

---

**Table 2 An overview of classical treatments indicated for the management of scabies in Australia**

| Study   | Drugs                  | Dosage                          | Treatment regimen          | Contraindication                     | Disadvantages                                                                 | Comments                                                                 |
|---------|------------------------|---------------------------------|-----------------------------|--------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Topical |                        |                                 |                             |                                      |                                                                                |                                                                          |
| [55, 56]| Benzyl benzoate        | 25 % solution one or several    | burning or stinging, pruritus, dermatitis, convulsions (rare) |                                      | In use since 1930s; possible neurological complications with misuse; withdrawn in the European Union due to neurotoxicity concerns |                                                                          |
| [23, 56–58]| Permethrin            | 5 % cream (8–14 h) then wash off | mild burning, itching, pruritus, erythema, tingling, persistent excoriations, dystonia (rare), convulsions (rare) |                                      | In use since the 1980s; relatively expensive; growing resistance among scabies mites poor compliance reported in mass community intervention programs |                                                                          |
| [59, 60]| Sulphur                | 2–10 % precipitate in petroleum base | noxious, malodorous messy; not given as first-line agents; multiple applications required; can cause skin irritation; has been used for centuries; indicated in infants, pregnant and lactating women; inexpensive |                                      |                                                                                |                                                                          |
| Oral    |                        |                                 |                             |                                      |                                                                                |                                                                          |
| [53, 61–63]| Ivermectin          | 200 μg/kg orally repeated after 1–2 weeks | transient side effects: gastrointestinal disorders; pustular rash, cellulitis; abdominal pain, diarrhoea, headache, vomiting, hypotension, toxic epidermal necrosis, mucosal drug eruption, fever, anorexia, lymph node swelling, eosinophilia, pain of joint and muscles, mazzotti reaction |                                      | In use since 1980’s (for the mass treatment of onchocerciasis, and filariasis); not approved for the treatment of typical scabies (except in Japan, Brazil, France); only indicated if symptoms persists 3 weeks after application of benzyl benzoate or permethrin; no oviidal activity, thus repeat treatment is required; one report of increased deaths among elderly patients during scabies outbreak in an institutional setting (1997); there has been considerable criticism on the validity of this report, no other studies have replicated these findings |                                                                          |
Acknowledgements
We would like to thank Mr Nirmal Mathew for accessing the reference material from author's host institution.

Author details
1 Faculty of Health, University of Canberra, Bruce 2617ACT, Australia. 2 College of Medicine and Veterinary Science, The University of Queensland, Sippy Downs 4558QLD, Australia. 3 School of Medicine and Pharmaceutical Sciences, The University of Western Australia, Nedlands 6009WA, Australia. 4 Translational Renal Research Group, Harry Perkins Institute of Medical Research, Nedlands 6009WA, Australia. 5 Charnwood, Canberra 2615ACT, Australia.

Received: 12 August 2014 Accepted: 10 June 2015
Published online: 01 July 2015

References
1. Orion E, Marcos B, Davidovici B, Wolf R. Itch and scratch: scabies and pediculosis. Clin Dermatol. 2006;24(3):168–75.
2. The Lancet Global Health Blog: “Scabies added to the World Health Organisation list of Neglected Tropical Diseases.” (2014). Available at: http://globalhealth.thelancet.com/2014/07/07/scabies-joins-list-where- neglected-tropical-diseases (last accessed 19 June 2015).
3. Conors C. Scabies treatment. Northern Territory Disease Control Bulletin. 1994;2:5–6.
4. Clucas DB, Carville KS, Connors C, Currie BJ, Carapetis JR, Andrews RM. Disease burden and health-care clinic attendances for young children in remote Aboriginal communities of northern Australia. Bull World Health Organ. 2008;86(6):275–81.
5. McLean FE. The elimination of scabies: a task for our generation. Int J Dermatol. 2005;44(10):1215–23.
6. Andrews RM, Keams T, Connors C, et al. A regional initiative to reduce skin infections amongst Aboriginal children living in remote communities of the Northern Territory, Australia. PLoS Negl Trop Dis. 2009;3(11):e554.
7. Kline K, McCarthy JS, Pearson M, Loukas A, Hotez PJ. Neglected tropical diseases of Oceania: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis. 2013;7(11):e1755.
8. Bouvresse S, Chosidow O. Scabies in healthcare settings. Curr Opin Infect Dis. 2010;23(2):111–8.
9. Walton SF, Holt DC, Currie BJ, Kemp DJ. Scabies: new face for a neglected disease. Adv Parasitol. 2004;57:309–76.
10. Jayaraj R, Hales B, Viberg L, Pizuto S, Holt D, Rolland JM, et al. A diagnostic test for scabies: IgE specificity for a recombinant allergen of Sarcoptes scabiei. Diagn Microbiol Infect Dis. 2011;71(4):403–7.
11. Strong M, Johnstone P. Interventions for treating scabies (Review). Cochrane Database Syst Rev. 2003;2:CD000320.
12. Haas N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W. Rapid and preferential seminal secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch Dermatol. 2002;138(11):1618–9.
13. FitzGerald D, Grainger RJ, Reid A. Interventions for preventing the spread of infestation in close contacts of people with scabies. Cochrane Database Syst Rev. 2014;2:CD009943.
14. Schienfeld N. Controlling scabies in institutional settings. Am J Clin Dermatol. 2004;5(1):31–7.
15. Paasch U, Haustein UF. Management of endemic outbreaks of scabies with allethrin, permethrin, and ivermectin. Int J Dermatol. 2000;39(6):463–70.
16. Stoevesandt J, Carle L, Leverkus M, Hamann H. Control of large institutional scabies outbreaks. J Dtsch Dermatol Ges. 2012;10(9):637–47.
17. Burkhart CG, Burkhart CN, Burkhart KM. An epidemiologic and therapeutic reassessment of scabies. Cutis. 2000;65:233–40.
18. Chosidow O. Clinical practices. Scabies. N Engl J Med. 2006;354(16):1718–27.
19. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med. 2010;362(8):717–25.
20. Hay RJ, Steer AC, Engelman D, Walton S. Scabies in the developing world—its prevalence, complications, and management. Clin Microbiol Infect. 2012;18(4):233–43.
21. Kemp DJ, Walton SF, Harumal P, Currie BJ. The Scourge of Scabies. Biologist. 2002;49(1):19–24.
22. Hicks MI, Elston DM. Scabies. Dermatol Ther. 2009;22(4):279–92.
23. Hengev UR, Currie BJ, Jager G, Lupi O, Schwartz RA. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis. 2006;6(12):769–79.
24. Goldust M, Rezaee M, Hemayat S. Treatment of scabies: comparison of permethrin 5% versus ivermectin. J Dermatol. 2012;39(6):545–7.
25. Usha V, Gopalakrishnan NT. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol. 2000;42(2):236–40.
26. Engelman D, Martin DL, Hay RJ, et al. Opportunities to investigate the effects of ivermectin mass drug administration on scabies. Parasit Vectors. 2013;6:106.
27. Haa K, Romani L, Filimore R, et al. Scabies community prevalence and mass drug administration in two Fijian villages. Int J Dermatol. 2014;53(6):399–45.
28. Keams T, Andrews R, Speare R, et al. Prevalence of scabies and strongyloidiasis before and after MDA in a remote Aboriginal community in Northern Territory, Australia. Int J Infect Dis. 2014;21(1):252.
29. Therapeutic Goods Administration (TGA). "Australian Public Assessment Report for Ivermectin (Stromectol)". 2013. Available at: http://www.tga.gov.au/ausp/ausap-ivermectin (last accessed 19 June 2015).
30. Australian Prescriber: “New drugs: ivermectin”, 1997. Available at http://www.australianprescriber.com/magazine/2003/77/9/new-drugs/149/ ivermectin (last accessed 19 June 2015).
31. NPS MedicineWise: “Ivermectin (Stromectol) for scabies. NPS Medicine Update”. 2014. Available at: http://www.nps.org.au/publications/consumer/ medicine-update/2014/ivermectin-stromectol-for-scabies (last accessed 24 March 2015).
32. Heukelbach J, Feldmeier H. Ectoparasites-the underestimated pandemic. Lancet. 2004;363(9412):889–91.
33. Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol. 2008;3(1):57–66.
34. Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol. 2009;145(7):784–1.
35. Teraida Y, Murayama N, Ikemura H, Morita T, Nagata M. Sarcoptes scabiei var. canis refractory to ivermectin treatment in two dogs. Vet Dermatol. 2010;21(6):608–12.
36. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis. 2004;39(1):18–22.
37. Pasay C, Walton S, Fischer K, Holt D, McCarthy J. PCR-based assay to survey for knockdown resistance to pyrethroid acaricides in human scabies mites (Sarcoptes scabiei var. hominis). Am J Trop Med Hyg. 2006;74(6):649–57.
38. Lebowitz MR. Failure of scabies treatment. N Z Med J. 1993;106(968):317–8.
39. Pasay C, Aflan L, Morgan M, et al. High-resolution melt analysis for the detection of a mutation associated with permethrin resistance in a population of scabies mites. Med Vet Entomol. 2008;22(1):82–8.
40. Fraser J. Permethrin: a Top End viewpoint and experience. Med J Aust. 1994;160(12):806–8.
41. van den Hoek JA, van de Weerd JA, Baayen TD, et al. A persistent problem with scabies in and outside a nursing home in Amsterdam: indications for resistance to lindane and ivermectin. Euro Surveill. 2008;13(48):19052.
42. Ly F, Caumes E, Ndaw CA, Ndiaye B, Mahe A. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ. 2009;87(6):424–30.
43. Nzo SDA, Iftikhar N, Batool F. Effectiveness of oral ivermectin for eradicating infesting mites in patients of scabies. J Pak Assoc Dermatol. 2011;21(2):87–92.
44. Gilmore SJ. Control strategies for endemic childhood scabies. PLoS ONE. 2011;6(1):e15990.
45. Moberg SA, Lowhagen GB, Harse K. An epidemic of scabies with unusual features and treatment resistance in a nursing home. J Am Acad Dermatol. 1994;31(2 Pt 1):242–4.
46. Yonkosky D, Ladia L, Gackenheimer L, Schultz MW. Scabies in nursing homes: an eradication program with permethrin 5 % cream. J Am Acad Dermatol. 1990;23(6 Pt 1):1133–6.

47. Nnoruka EN, Agu CE. Successful treatment of scabies with oral ivermectin in Nigeria. Trop Dr. 2001;31(1):15–8.

48. Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg. 2000;94(1):92–6.

49. Sagib M, Afridi IU, Ali A, Jahangir M. Scabies: Safety of Permethrin and ivermectin. Professional Med J. 2012;19(1):86.

50. Huffer SE, Currie BJ. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis. 1998;2(3):152–4.

51. Coskey RJ. Scabies-resistance to treatment with crotamiton. Arch Dermatol. 1979;115(1):109.

52. Glaziou P, Cartel J, Alzeu P, Briot C, Moulia-Pelat J, Martin P. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol. 1993;44(4):331–2.

53. Brooks P, Grace R. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health. 2002;38(4):401–4.

54. Fujimoto K, Kawasaki Y, Morimoto K, Kikuchi I, Kawana S. Treatment for crusted scabies: limitations and side effects of treatment with ivermectin. J Nippon Med Sch. 2014;81(3):157–63.

55. Roos TC, Roos S, Merk HF, Bickers DR. Pharmacotherapy of ectoparasitic infections. Drugs. 2001;61(8):1067–88.

56. Walker G, Johnstone P. Interventions for treating scabies (Cochrane Review). Cochrane Database Syst Rev. 2003;CD000320.

57. Coleman CI, Gillespie EL, White CM. Probable topical permethrin-induced neck dystonia. Pharmacotherapy. 2005;25(3):448–50.

58. Schultz MW, Gomez M, Hansen RC, Mills I, Menter A, Rodgers H, et al. Comparative study of 5 % permethrin cream and 1 % lindane lotion for the treatment of scabies. Arch Dermatol. 1990;126(2):167–70.

59. Singalavandjan S, Limponsaranusk W, Sophonsukkul S. A comparative study between 10 % sulfur ointment and 0.3 % gamma benzene hexachloride gel in the treatment of scabies in children. J Med Assoc Thail. 2003;86(S5):31–6.

60. Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J. 2005;81(951):7–11.

61. del Giudice P. Ivermectin in scabies. Curr Opin Infect Dis. 2002;15(2):123–6.

62. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet. 1997;349(9059):1144–5.